Moderna Shares Surge on Positive Cancer Vaccine Trial Data
Moderna's shares more than doubled in value after late-stage clinical data showed promising results for its personalized mRNA cancer therapy, intismeran. The treatment, developed with Merck, demonstrated a reduced risk of recurrence and spread of skin cancer when combined with Keytruda. This development reinvigorates investor confidence that Moderna’s mRNA technology can extend beyond infectious diseases into oncology, potentially creating new revenue streams for the company. The positive data also triggered broader gains in biotech stocks, including BioNTech and Novavax, while Merck shares rose to a record high due to its role in the trial. Analysts highlighted that an effective cancer treatment could be extremely profitable if approved, with Leerink Partners raising their sales projection for intismeran by 2032. The sharp rise in Moderna's stock also led to significant losses for short sellers, who now face pressure as shares trade at a two-year high. With over 15 times the average trading volume and a large short interest base, there are concerns of further upward momentum driven by covering activity.
Tickers: $BNTX $MRK $MRNA $NVAX
Topics: biotech cancer vaccine market reaction mRNA technology